Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Suliman

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 21, 2008
Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patientsAlessandro Valli, Juan J Carrero, Abdul Rashid Qureshi, et al.
European Journal of Clinical Investigation|November 22, 2008
Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patientsG Metry, P Stenvinkel, A R Qureshi, et al.
Antioxidants & Redox Signaling|October 13, 2006
Elevated serum 8-oxo-dG in hemodialysis patients: a marker of systemic inflammation?Siamak Haghdoost, Yukio Maruyama, Roberto Pecoits-Filho, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortalityMengli Tong, Juan Jesús Carrero, A Rashid Qureshi, et al.
Journal of the American Society of Nephrology : JASN|May 23, 2003
Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapyMohammed E Suliman, Olof Heimbürger, Peter Bárány, et al.
QJM : Monthly Journal of the Association of Physicians|February 23, 2008
The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortalityM E Suliman, A R Qureshi, J J Carrero, et al.
Frontiers in Nutrition|March 20, 2023
Central obesity as assessed by conicity index and a-body shape index associates with cardiovascular risk factors and mortality in kidney failure patientsKakei Ryu, Mohamed E Suliman, Abdul Rashid Qureshi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 2, 2009
Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levelsJuan J Carrero, Anna Witasp, Peter Stenvinkel, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 25, 2006
J-shaped mortality relationship for uric acid in CKDMohamed E Suliman, Richard J Johnson, Elvia García-López, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 31, 2007
Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKDJonas Axelsson, Anna Witasp, Juan Jesús Carrero, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 21, 2008
Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patientsAlessandro Valli, Juan J Carrero, Abdul Rashid Qureshi, et al.
European Journal of Clinical Investigation|November 22, 2008
Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patientsG Metry, P Stenvinkel, A R Qureshi, et al.
Antioxidants & Redox Signaling|October 13, 2006
Elevated serum 8-oxo-dG in hemodialysis patients: a marker of systemic inflammation?Siamak Haghdoost, Yukio Maruyama, Roberto Pecoits-Filho, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortalityMengli Tong, Juan Jesús Carrero, A Rashid Qureshi, et al.
Journal of the American Society of Nephrology : JASN|May 23, 2003
Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapyMohammed E Suliman, Olof Heimbürger, Peter Bárány, et al.
QJM : Monthly Journal of the Association of Physicians|February 23, 2008
The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortalityM E Suliman, A R Qureshi, J J Carrero, et al.
Frontiers in Nutrition|March 20, 2023
Central obesity as assessed by conicity index and a-body shape index associates with cardiovascular risk factors and mortality in kidney failure patientsKakei Ryu, Mohamed E Suliman, Abdul Rashid Qureshi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 2, 2009
Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levelsJuan J Carrero, Anna Witasp, Peter Stenvinkel, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 25, 2006
J-shaped mortality relationship for uric acid in CKDMohamed E Suliman, Richard J Johnson, Elvia García-López, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 31, 2007
Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKDJonas Axelsson, Anna Witasp, Juan Jesús Carrero, et al.
Pageof 9